Skip to main content

Table 3 Final subject disposition by group and visit

From: A randomized, double blind, placebo and active comparator controlled pilot study of UP446, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin

   Group
   UP446250 mgs/day UP446500 mgs/day Celecoxib 200 mgs/day Placebo
Visit Baseline 15 15 15 15
  30 Days 15 15 13 15
  60 Days 14 13 13 13
  90 Days 14 13 12 13